Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | August 01, 2026 | August 04, 2026 |
| Kodiak Sciences Inc.KOD · Entity 4388 | Director | June 30, 2026 | July 02, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
| Neurogene Inc.AQXP · Entity 5160 | Director | March 23, 2017 | March 27, 2017 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 22,359 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Exercise / conversion · Acquired 403 · Balance 22,359 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 403 |
Reported balance
After 2026-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-01 · Grant · Acquired 403 · Balance 403 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-01 · Exercise / conversion · Disposed 403 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs.
Kodiak Sciences Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2036-06-29 | Direct | 17,731 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 17,731 · Balance 17,731 F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,469 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 22,469 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Neurogene Inc.
Report date March 23, 2017 · Filed March 27, 2017
This filing explicitly reported no securities owned.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.29 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 26,342 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2026 Filed Aug 4, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0001454983-26-000008 · form4-08042026_080829.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 403 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0001454983-26-000008 · form4-08042026_080829.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 403 Underlying: Class A Ordinary Shares · 403 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 403 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001454983-26-000008 · form4-08042026_080829.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:55 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 17,731 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0001454983-26-000006 · form4-07022026_090730.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,731 Underlying: Common Stock · 17,731 shares Expires 2036-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:21 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 766 | $0.00 Strike: $499.86 | $0.00 |
DisclosureSEC source: 0001628280-26-044340 · wk-form4_1781814108.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766 Underlying: Common Stock · 766 shares Expires 2036-06-17 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:21 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-044340 · wk-form4_1781814108.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,469 F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001213900-26-069250 · marketforms-73187.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001454983-26-000004 · form4-06022026_080618.xml · derivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001454983-26-000004 · form4-06022026_080618.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,026 Underlying: Class A Ordinary Shares · 2,026 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 12,158 | $0.00 Strike: $48.38 | $0.00 |
DisclosureSEC source: 0001454983-26-000004 · form4-06022026_080618.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,158 Underlying: Class A Ordinary Shares · 12,158 shares Expires 2036-05-28 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001454983-26-000004 · form4-06022026_080618.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 80 | $519.98 | $41,598.40 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 12 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,015 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.68 to $520.28, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 782 | $518.76 | $405,668.76 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 11 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,095 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.30 to $519.29, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,497 | $517.59 | $774,835.37 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 10 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,877 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.28 to $518.27, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 723 | $516.87 | $373,693.97 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 9 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,374 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.28 to $517.27, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 657 | $515.92 | $338,960.69 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 8 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,097 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.26 to $516.22, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 343 | $514.67 | $176,531.50 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 7 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,754 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.17 to $515.16, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $512.97 | $20,518.80 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 6 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,097 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 439 | $512.50 | $224,988.47 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 5 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,137 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.91 to $512.88, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 610 | $511.40 | $311,951.99 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,576 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $510.89 to $511.87, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 151 | $510.36 | $77,064.04 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,186 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.89 to $510.85, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 320 | $508.24 | $162,637.44 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,337 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $508.11 to $508.89, inclusive. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $506.68 | $20,267.00 |
DisclosureSEC source: 0001628280-26-037830 · wk-form4_1779487311.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,657 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.42 to $507.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 22:09 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001628280-26-011211 · wk-form4_1771970943.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 22:09 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 2,500 | $7.36 | $18,400.00 |
DisclosureSEC source: 0001628280-26-011211 · wk-form4_1771970943.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2026 Filed Feb 4, 2026 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 683 | $0.00 | $0.00 |
DisclosureSEC source: 0001454983-26-000002 · form4-02042026_110254.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on February 1, 2026; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on February 1, 2026; there was no expiration date for the RSUs. Read SEC document |
| February 01, 2026 Filed Feb 4, 2026 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 683 | $0.00 | $0.00 |
DisclosureSEC source: 0001454983-26-000002 · form4-02042026_110254.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 683 Underlying: Class A Ordinary Shares · 683 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on February 1, 2026; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on February 1, 2026; there was no expiration date for the RSUs. Read SEC document |
| February 01, 2026 Filed Feb 4, 2026 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001454983-26-000002 · form4-02042026_110254.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| January 26, 2026 Filed Jan 26, 2026 23:02 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001628280-26-003491 · wk-form4_1769468543.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2027-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| January 26, 2026 Filed Jan 26, 2026 23:02 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 4,000 | $16.46 | $65,840.00 |
DisclosureSEC source: 0001628280-26-003491 · wk-form4_1769468543.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · derivative · entry 18 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · derivative · entry 17 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $530.21 | $21,208.40 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 16 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,197 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 440 | $528.60 | $232,585.58 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 15 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,237 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.18 to $528.94, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $527.85 | $105,569.68 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 14 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,677 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.17 to $528.15, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 120 | $526.68 | $63,201.96 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 13 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,877 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.17 to $527.09, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 153 | $524.49 | $80,247.05 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 12 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,997 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.31 to $524.71, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 811 | $523.66 | $424,687.37 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 11 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,150 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.31 to $524.29, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,434 | $522.70 | $749,557.11 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 10 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,961 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.30 to $523.29, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,094 | $521.79 | $570,835.74 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 9 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,395 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.22 to $522.21, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 308 | $520.68 | $160,369.38 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 8 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,489 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.21 to $521.18, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,355 | $519.67 | $704,146.62 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 7 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,797 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.18 to $520.15, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 835 | $518.53 | $432,974.14 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 6 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,152 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.155 to $519.04, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 645 | $517.51 | $333,795.95 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 5 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,987 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.15 to $518.10, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 919 | $515.64 | $473,876.19 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,632 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.19 to $516.10, inclusive. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 146 | $514.67 | $75,142.40 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,551 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.03 to $514.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 6,000 | $16.46 | $98,760.00 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 2,500 | $7.36 | $18,400.00 |
DisclosureSEC source: 0001628280-25-052411 · wk-form4_1763158342.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019334 · form4-07032025_080736.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 1,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on July 1, 2025; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on July 1, 2025; there was no expiration date for the RSUs. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019334 · form4-07032025_080736.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,101 Underlying: Class A Ordinary Shares · 1,101 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on July 1, 2025; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on July 1, 2025; there was no expiration date for the RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.